3D Volumetric Measurements of GH Secreting Adenomas Correlate with Baseline Pituitary Function, Initial Surgery Success Rate, and Disease Control

Abstract

There is scarce data on the clinical utility of volume measurement for growth hormone (GH)-secreting pituitary adenomas. The current study objective was to assess the association between pituitary adenoma volumes and baseline endocrine evaluation, initial surgical success rate, and disease control among patients with acromegaly. A retrospective cohort study was conducted at a clinical research center including patients with acromegaly due to GH-secreting pituitary adenomas. Baseline hormonal evaluation and adenoma characteristics according to MRI were collected. Volumetric measurements of pituitary adenomas were performed using a semi-automated lesion segmentation and tumor-volume assessment tools. Rates of post-operative medical treatment, radiation therapy, and re-operation were gathered from the patients’ medical records. Twenty seven patients (11 females) were included, median age 21.0 years (interquartile range 29 years, range 3–61 years). Patients harboring adenomas with a volume <2 000 mm³ had higher chance to achieve disease remission [94.1% (n=16) vs. 50.0% (n=4), p<0.05]. Adenoma volumes positively correlated with baseline plasma GH levels before and after oral glucose administration, and with plasma IGF-I and PRL levels. Adenoma volume had negative correlation with morning plasma cortisol levels. Finally, patients harboring larger adenomas required 2nd surgery and/or medical treatment more often compared with subjects with smaller adenomas. Accurate 3D volume measurement of GH-secreting pituitary adenomas may be used for the prediction of initial surgery success and for disease control rates among patients with a GH-secreting pituitary adenomas and performs better than standard size assessments.

Key words

volumetric measurement - acromegaly - hypopituitarism

• References

• 1 Thorner MO, Frohman LA, Leong DA, Thominet J, Downs T, Hellmann P, Chitwood J, Vaughan JM, Vale W. Extrahypothalamic growth-hormone-releasing factor (GRF) secretion is a rare cause of acromegaly: Plasma GRF levels in 177 acromegalic patients. J Clin Endocrinol Metab 1984; 59: 846-849
• 2 Melmed S. Acromegaly pathogenesis and treatment. J Clin Invest 2009; 119: 3189-3202
• 3 Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: Epidemiology, pathogenesis, and management. Endocr Rev 2004; 25: 102-152
• 4 Jonas C, Maiter D, Alexopoulou O. Evolution of glucose tolerance after treatment of acromegaly: A study in 57 patients. Horm Metab Res 2016; 48: 299-305
• 5 Lodish MB, Trivellin G, Stratakis CA. Pituitary gigantism: Update on molecular biology and management. Curr Opin Endocrinol Diabetes Obes 2016; 23: 72-80
• 6 Ceccato F, Lizzul L, Zilio M, Barbot M, Denaro L, Emanuelli E, Alessio L, Rolma G, Manara R, Saller A, Boscaro M, Scaroni C. Medical Treatment for Acromegaly does not increase the risk of central adrenal insufficiency: A long-term follow-up study. Horm Metab Res 2016; 48: 514-519
• 7 Abu Dabrh AM, Mohammed K, Asi N, Farah WH, Wang Z, Farah MH, Prokop LJ, Katznelson L, Murad MH. Surgical interventions and medical treatments in treatment-naïve patients with acromegaly: Systematic review and meta-analysis. J Clin Endocrinol Metab 2014; 99: 4003-4014
• 8 Katznelson L, Laws ER, Melmed S, Molitch ME, Murad MH, Utz A, Wass JaH. acromegaly: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014; 99: 3933-3951
• 9 Shimon I, Cohen ZR, Ram Z, Hadani M. Transsphenoidal surgery for acromegaly: Endocrinological follow-up of 98 patients. Neurosurgery 2001; 48: 1239-43-5
• 10 Nomikos P, Buchfelder M, Fahlbusch R. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical “cure”. Eur J Endocrinol 2005; 152: 379-387
• 11 Buhk J-H, Jung S, Psychogios MN, Göricke S, Hartz S, Schulz-Heise S, Klingebiel R, Forsting M, Brückmann H, Dörfler A, Jordan M, Buchfelder M, Knauth M. Tumor volume of growth hormone-secreting pituitary adenomas during treatment with pegvisomant: a prospective multicenter study. J Clin Endocrinol Metab 2010; 95: 552-558
• 12 Schwyzer L, Starke RM, Jane JA, Oldfield EH. Percent reduction of growth hormone levels correlates closely with percent resected tumor volume in acromegaly. J Neurosurg 2015; 122: 798-802
• 13 Bornstein SR, Allolio B, Arlt W, Barthel A, Don-Wauchope A, Hammer GD, Husebye ES, Merke DP, Murad MH, Stratakis CA, Torpy DJ. Diagnosis and treatment of primary adrenal insufficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2016; 101: 364-389
• 14 Chohan MO, Levin AM, Singh R, Zhou Z, Green CL, Kazam JJ, Tsiouris AJ, Anand VK, Schwartz TH. Three-dimensional volumetric measurements in defining endoscope-guided giant adenoma surgery outcomes. Pituitary 2016; 19: 311-321
• 15 Bourdelot A, Coste J, Hazebroucq V, Gaillard S, Cazabat L, Bertagna X, Bertherat J. Clinical, hormonal and magnetic resonance imaging (MRI) predictors of transsphenoidal surgery outcome in acromegaly. Eur J Endocrinol 2004; 150: 763-771
• 16 van Bunderen CC, van Varsseveld NC, Baayen JC, van Furth WR, Aliaga ES, Hazewinkel MJ, Majoie CBLM, Freling NJM, Lips P, Fliers E, Bisschop PH, Drent ML. Predictors of endoscopic transsphenoidal surgery outcome in acromegaly: Patient and tumor characteristics evaluated by magnetic resonance imaging. Pituitary 2013; 16: 158-167
• 17 Miller BH, Gore AC. Alterations in hypothalamic insulin-like growth factor-I and its associations with gonadotropin releasing hormone neurones during reproductive development and ageing. J Neuroendocrinol 2001; 13: 728-736
• 18 Daftary SS, Gore AC. IGF-1 in the brain as a regulator of reproductive neuroendocrine function. Exp Biol Med 2005; 230: 292-306